Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899795 · ClinicalTrials.gov registry record
Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 35
- Enrollment target
NCT00899795: Completed study, sponsored by OHSU Knight Cancer Institute.
NCT00899795 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899795 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy volunteers in the laboratory may help doctors learn more about changes that occur in bone marrow stromal (connective tissue) cells. It may also help doctors understand the effects of alkylating agents on bone marrow stromal cells. PURPOSE: This laboratory study is evaluating stromal cells in patients with acute myeloid leukemia, myelodysplastic syndromes, or Fanconi anemia; in patients who were exposed to alkylating agents; and in healthy volunteers.
Interventions
- PROCEDURE biopsy
- OTHER flow cytometry
- GENETIC cytogenetic analysis
- GENETIC fluorescence in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2002-06 |
| Est. Completion | 2010-10 |
What the finished NCT00899795 record still lists
NCT00899795 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 35 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which biopsy is the first listed.
NCT00899795 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899795 about?
NCT00899795 is a clinical study titled "Evaluating Cell Damage in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Fanconi Anemia; in Patients Who Were Exposed to Alkylating Agents; and in Healthy Volunteers". RATIONALE: Studying samples of bone marrow from patients with cancer and from healthy volunteers in the laboratory may help doctors learn more about changes that occur in bone marrow stromal (connective tissue) cells. It may also help doctors understand the effects of alkylating agents on bone marro...
What is the current status of trial NCT00899795?
This trial is currently completed. The enrollment target is 35 participants. The study started on 2002-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00899795?
The interventions under investigation include: biopsy (PROCEDURE), flow cytometry (OTHER), cytogenetic analysis (GENETIC), fluorescence in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00899795?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia